FDA approves CTI BioPharma's bone marrow cancer drug

CTI Biopharma

01/03/2022 24:33

Feb 28 (Reuters) - CTI BioPharma Corp  CTIC.O  said on
Monday the U.S. Food and Drug Administration approved its drug
Vonjo (pacritinib) for treating adult patients with a type of
bone marrow cancer who also have low blood platelet count.
    The nod makes it the third approved drug for the disease.

 (Reporting by Mrinalika Roy and Rachna Dhanrajani in Bengaluru;
editing by Uttaresh.V)
 ((RachnaManojkumar.Dhanrajani@thomsonreuters.com;))